Rockville-based RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company with a primary focus on therapeutic peptide development. Specifically, the firm's flagship project is thymosin beta 4, which aids in tissue and organ protection, repair, and regeneration. The drug developer has several promising projects in its pipeline, including RGN-259 - a preservative-free topical eye drop used for corneal tissue regeneration targeted to aid in the recovery of damaged corneas afflicted by disease, injury, or other pathology. Additionally, the company is developing RGN-352, an injectable formulation utilized to treat medical indications such as central and peripheral nervous system diseases and cardiovascular diseases. RGN-137 is a topical gel that RegeneRx Biopharmaceuticals has also been developing, with usage intended for scar tissue reduction and dermal wound healing. The company's strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. add even more potential to RegeneRx's innovative pipeline. The company was originally incorporated as Alpha 1 Biomedicals, Inc. in 1982, but it changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000.